IMAGING

Valérie VILGRAIN

Valérie Vilgrain is Director of the Radiology Department at the University Hospital Beaujon in Clichy (France) and full professor at the University Paris Diderot (France). Her research topics are diagnostic and interventional imaging of the liver and bile ducts with CT and MRI. She received her MD from the René Descartes Medical University of Paris in 1985. She completed a residency in Radiology and was assistant Professor in Radiology at the University Hospital Beaujon. She is member of several international societies (Radiological Society of North America, European Society of Radiology, European Society of Gastroenterology and Abdominal Radiology), and the French Radiology Society. She was responsible for the Education Program Committee of the French annual meeting from 2000 to 2008 and she is currently Vice-Director of the French Radiology Society. She published numerous peer-reviewed articles (h-index: 57) and is reviewer for many renowned journals including European Radiology, Liver Transplantation, Hepatology, Journal of Hepatology, Radiology, and European Journal of Radiology. She is associate editor of Radiology.

Hepatology. 2022 ;In press. Reliability of extracellular contrast versus gadoxetic acid in assessing small liver lesions using liver imaging reporting and data system v.2018 and European association for the study of the liver criteria.  Rimola J, Sapena V, Brancatelli G, Darnell A, Forzenigo L, Mähringer-Kunz A, Paisant A, Renzulli M, Schima W, Terraz S, Valls C, Wagner M, Ayuso C, Vilgrain V, Reig M, Ronot M. PubMed

Hepatol Int. 2022;16:509-522.  Conventional and artificial intelligence-based imaging for biomarker discovery in chronic liver disease. Dana J, Venkatasamy A, Saviano A, Lupberger J, Hoshida Y, Vilgrain V, Nahon P, Reinhold C, Gallix B, Baumert TF. PubMed

Cells. 2021;10:2733. Steatosis alters the activity of hepatocyte membrane transporters in obese rats. Pastor CM, Vilgrain V. PubMed

Eur Radiol Exp. 2021;5:42. Concentrations and pharmacokinetic parameters of MRI and SPECT hepatobiliary agents in rat liver compartments. Pastor CM, Joly F, Vilgrain V, Millet P. PubMed

Eur Radiol. 2021;31:3417-3426. Hepatospecific MR contrast agent uptake on hepatobiliary phase can be used as a biomarker of marked β-catenin activation in hepatocellular adenoma. Reizine E, Ronot M, Ghosn M, Calderaro J, Frulio N, Bioulac-Sage P, Trillaud H, Vilgrain V, Paradis V, Luciani A. PubMed

J Hepatol. 2020;72:937-945. Comparison of extracellular and hepatobiliary MR Contrast agents for the diagnosis of small HCCs. APaisant, V Vilgrain, J Riou, F Oberti, O Sutter, V Laurent, A Rodes, B Guiu, C Cassinotto, H Trillaud, I Bricault, S Michalak, O Bruno, M Ronot, C Aubé. PubMed

Dig Dis Sci. 2019;64:934-950. Hepatocellular carcinoma: current imaging modalities for diagnosis and prognosis. Ronot M, Purcell Y, Vilgrain V. PubMed

Eur Radiol. 2019;In press. Iso- or hyperintensity of hepatocellular adenomas on hepatobiliary phase does not always correspond to hepatospecific contrast-agent uptake: importance for tumor subtyping. Reizine E, Ronot M, Pigneur F, Purcell Y, Mulé S, Dioguardi Burgio M, Calderaro J, Amaddeo G, Laurent A, Vilgrain V, Luciani A. PubMed

J Hepatol. 2018;69:182-236. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. Galle PR, Forner A, Llovet JM, Mazzaferro V, Piscaglia F, Raoul JL, Schirmacher P, Vilgrain V. PubMed

AJR Am J Roentgenol. 2018;210:775-779. Focal nodular hyperplasia after treatment with Oxaliplatin: A multiinstitutional series of cases diagnosed at MRI. Furlan A, Brancatelli G, Dioguardi Burgio M, Grazioli L, Lee JM, Murmura E, Lucidarme O, Strauss C, Rode A, Ronot M, Vilgrain V. PubMed

Lancet Oncol. 2017;18:1624-1636. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux GP, Sibert A, Bouattour M, Lebtahi R, Allaham W, Barraud H, Laurent V, Mathias E, Bronowicki JP, Tasu JP, Perdrisot R, Silvain C, Gerolami R, Mundler O, Seitz JF, Vidal V, Aubé C, Oberti F, Couturier O, Brenot-Rossi I, Raoul JL, Sarran A, Costentin C, Itti E, Luciani A, Adam R, Lewin M, Samuel D, Ronot M, Dinut A, Castera L, Chatellier G; SARAH Trial Group. PubMed

JMIR Res Protoc. 2017;6:e17. VESPRO: An individual patient data prospective meta-analysis of selective internal radiation therapy versus Sorafenib for advanced, locally advanced, or recurrent hepatocellular carcinoma of the SARAH and SIRveNIB trials. Gebski V, Gibbs E, Gandhi M, Chatellier G, Dinut A, Pereira H, Chow PK, Vilgrain V. PubMed

Eur J Drug Metab Pharmacokinet. 2017;42:657-667. Liver perfusion modifies Gd-DTPA and Gd-BOPTA hepatocyte concentrations through transfer clearances across sinusoidal membranes. Daire JL, Leporq B, Vilgrain V, Van Beers BE, Schmidt S, Pastor CM5. PubMed

Semin Ultrasound CT MR. 2016;37:561-572. Avoiding pitfalls in the interpretation of Gadoxetic Acid-enhanced Magnetic Resonance Imaging. Dioguardi Burgio M, Ronot M, Paulatto L, Terraz S, Vilgrain V, Brancatelli G. PubMed

Liver Int. 2016;36:631-3. Multiparametric magnetic resonance imaging in patients with chronic liver disease: are we there yet? Ronot M, Vilgrain V. PubMed

J Hepatol. 2016;64:708-16. Insights into the diagnosis of hepatocellular carcinomas with hepatobiliary MRI.Vilgrain V, Van Beers BE, Pastor CM. PubMed

Eur Radiol. 2016;26:921-31. ESGAR consensus statement on liver MR imaging and clinical use of liver-specific contrast agents. Neri E, Bali MA, Ba-Ssalamah A, Boraschi P, Brancatelli G, Alves FC, Grazioli L, Helmberger T, Lee JM, Manfredi R, Martì-Bonmatì L, Matos C, Merkle EM, Op De Beeck B, Schima W, Skehan S, Vilgrain V, Zech C, Bartolozzi C. PubMed

Radiology. 2015;274:379-86. Advanced fibrosis: Correlation between pharmacokinetic parameters at dynamic gadoxetate-enhanced MR imaging and hepatocyte organic anion transporter expression in rat liver. Lagadec M, Doblas S, Giraudeau C, Ronot M, Lambert SA, Fasseu M, Paradis V, Moreau R, Pastor CM, Vilgrain V, Daire JL, Van Beers BE. PubMed

Best Pract Res Clin Gastroenterol. 2014;28:795-812. Hepatocellular carcinoma: diagnostic criteria by imaging techniques. Ronot M, Vilgrain V. PubMed

Clin Res Hepatol Gastroenterol. 2014;38:681-8. Imaging of benign hepatocellular lesions: current concepts and recent updates. Ronot M, Vilgrain V. PubMed

Trials. 2014;15:474.  Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial. Vilgrain V, Abdel-Rehim M, Sibert A, Ronot M, Lebtahi R, Castéra L, Chatellier G; SARAH Trial Group. PubMed